MedTrace Logo

Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia

NCT05177289 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-09-29

No results posted yet for this study

Summary

This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the prevention and management of chemotherapy-induced alopecia (CIA). Therefore, we hypothesize that PBMT can reduce the severity of CIA in gynecological and breast cancer patients, increasing the patient's QoL.

Conditions

  • Chemotherapy-induced Alopecia

Interventions

DEVICE

Theradome® LH80 pro

The Theradome LH80 pro is a wearable laser helmet device, which uses red laser light to stop hair loss, thicken existing hair and stimulate the growth of new hair.

DEVICE

Scalp cooling

Scalp cooling is a standard treatment that is applied to prevent hair loss during chemotherapy.

Sponsors & Collaborators

  • Jessa Hospital

    lead OTHER

Principal Investigators

  • Jeroen Mebis, Prof. Dr. · Jessa Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2025-01-31
Completion
2030-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05177289 on ClinicalTrials.gov